Clinical Trials Browser

Phase 3 × Interventional × aumolertinib × Clear all

NCT07183189 2025-12-18

A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT04923906 2024-11-25

Aumolertinib with or Without Chemotherapy As 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Sensitizing EGFR Mutations

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04687241 2024-11-07

Almonertinib Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB Non-Small Cell Lung Cancer With EGFR-sensitive Mutations

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05493501 2024-05-02

Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer

Phase 3 Terminated

8 enrolled 7 charts

NSCLC

NCT06043973 2023-09-21

Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance

Phase 3 Recruiting

Advanced Non-small Cell Lung Cancer

NCT05800223 2023-04-05

Armatinib Alone or in Combination With SRT for Brain Metastases EGFR-mutated Non-small Cell Lung Cancer

Phase 3 Recruiting

Non-small Cell Lung Cancer Metastatic

NCT05768490 2023-03-14

Early or Delayed Intervention of Brain Radiotherapy Combined With Almonertinib in EGFR Mutated NSCLC With Brain Metastases

Phase 3 Recruiting

Brain Neoplasms

NCT03849768 2023-01-20

A Study to Evaluate Safety and Efficacy of HS-10296 as First-Line Treatment in Patients

Phase 3 Unknown

429 enrolled 18 charts

Carcinoma, Non-Small-Cell Lung

NCT04951635 2022-06-16

A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT04762459 2022-02-24

APEX

Phase 3 Enrolling by invitation

Carcinoma, Non-Small-Cell Lung

NCT04951648 2021-07-07

A Phase III Study to Assess the Efficacy and Safety of Almonertinib Versus Platinum-based Chemotherapy as First-line Therapy in Patients With Locally Advanced or Metastatic NSCLC Harbouring Uncommon EGFR Mutation

Phase 3 Unknown

Carcinoma, Non-Small-Cell Lung

NCT04500704 2020-08-05

ACROSS1

Phase 3 Unknown

Carcinoma, Non-Small-Cell Lung

NCT04500717 2020-08-05

ACROSS2

Phase 3 Unknown

Carcinoma, Non-Small-Cell Lung